SPARC gets Orphan Drug Designation from USFDA

08 Jul 2019 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received Orphan Drug Designation from the US Food and Drug Administration (USFDA) for SCO-088 for the treatment of patients with Chronic Myeloid Leukemia (CML).

This is an important milestone in company’s journey to provide solution for patients who are not responding to the existing treatments available in the market. SCO-088 will fill the gap in the treatment of resistant CML.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

128.55 0.80 (0.63%)
21-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Syngene Internation. 603.20
Indegene 480.20
CMS Info Systems 328.80
Sagility 51.50
Smartworks Coworking 444.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×